Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| The effect of (Oligonol) and (Oligonol + metformin) on the components of Metabolic Syndrome in obese individuals- A randomized, double-blind, factorial clinical trial. | Amino Up Chemical Co., Ltd. | Terminated | Oligonol | 3 | SDRG- Amino Up 1 | KFMRC-J |
| Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled | Sanofi | Completed | Lantus® | 3 | LANTU_C_02762 | KFUH |
| "Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy" | Inovio Pharmaceuticals, Inc. | Completed | NO-4700 + CELLECTRA™ 2000 (device) | 2 | MERS-201 | KSMC |
| Study of Aflibercept in Uveitic Macular EDema (SAUD study) | King Khalid Specialist Hospital | Rejected | Aflibercept | 3b | 18176 | KKESH |
| "Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial with an open-label extension that investigates the effect of the addition of dulaglutide (0.75 and 1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baseline in hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus" | Eli Lilly | Ongoing | Dulaglutide 0.75 /1.5 mg | 3 | H9X-MC-GBGC | KKUH |
| Standard Induction with Basiliximab versus No-Induction in Low Immunological Risk Kidney Transplant Recipients Prospective Randomized Double Blind Controlled Clinical Trial | King Faisal Specialist Hospital and Research Centre | Ongoing | BASILIXIMAB (SIMULECT) | 3 | 2191177 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| SPIMACO Biosimilar Insulin Phase III Study: Clinical Efficacy and Safety | SPIMACO | Ongoing | Fastulin R / Normulin N | 3 | N/A (version 1.4) Aug 2011 | KFMC |
| "Somatostatin as inflow modulator in Adult-to-Adult living donor liver transplantation. A randomized, double-blind, placebo-controlled trial" | King Faisal Specialist Hospital and Research Centre | Ongoing | Somatostatin | 3 | 2191109 | KFSH & RC-R |
| Single arm Phase I/II study of the safety, tolerability and efficacy of the Tocilizumab followed by cisplatin/docetaxel in patients with triple negative locally advanced breast cancer | King Faisal Specialist Hospital and Research Centre | Ongoing | TOCILIZUMAB (ACTEMRA) | 1/2 | 2181156 | KFSH&RC-R |
| Single arm Phase I/II study of the safety, tolerability and efficacy of the investigational anti PD-L1 monoclonal antibody Durvalumab in combination with Paclitaxel in patients with metastatic triple negative PD-L1 positive breast cancer | AstraZeneca | Ongoing | Paclitaxel | 1 | ESR-14-10649 | KFSH & RC-R |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.